ImmunOs Therapeutics AG raises CHF 15M in Series A Financing


Based in Schlieren, ImmunOS Therapeutics developing the next generation of cancer treatments has raised CHF 15M in Series A round co-led by the Basel life sciences venture capital firm BioMedPartners and Pfizer Ventures. Former Novartis CEO Daniel Vasella will join the board of the start-up. 


ImmunOs Therapeutics AG, a spin-off company of the University of Zurich and the University of Basel, is the leading developer of a next-generation innate immunity focused immunotherapy platform for cancer. The company's lead agent, iosH2, a potential new cancer treatment for both solid and liquid tumours. Today, the biotech company has announced the conclusion of its series A round, raising CHF15 million. In addition to the co-lead investors BioMedPartners and Pfizer Ventures, other participants include Redalpine, Schroder Adveq, Wille Finance AG, BERNINA BioInvest Ltd alongside new private and existing investors. The financing will be used to complete the first-in-human trials with the company’s lead agent,  broaden the iosH platform by advancing additional preclinical programs focusing on both cancer and auto-immunity. Osiris Marroquin Belaunzaran, CSO and co-founder of ImmunOs, says: “It is with great pleasure to see our early research based on HLA open conformer modulation of immune cells advancing toward a clinical drug candidate for human studies. Targeting the innate immune system to modulate the tumour microenvironment has been a key strategy for ImmunOs, and together with foundational approaches targeting the adaptive immune system such as PD-1 antibodies, we aim to produce a strong therapeutic benefit in difficult-to-treat cancer indications." Daniel Vasella joins board In line with the the financing round, ImmunOs Therapeutics has expanded its Board of Directors to include four new  members: Markus Hosang of BioMedPartners; Michael Baran of Pfizer Inc.; Reinhard Ambros, former head Novartis Venture Fund; and Daniel Vasella, former Chairman and CEO Novartis. "Immunos adds to existing treatment modalities and thus has the potential to provide novel medicines to cancer patients who do not obtain a long-term benefit from current therapies", said Markus Hosang from BioPartners. Michael Baran added: “Advances in understanding the role of the innate immune system is opening up opportunities to expand the potential of cancer immunotherapy. Pfizer Ventures is enthusiastic to support this emerging area through our investment in ImmunOs.”(Press release/ran)